Pfiz­er dumps a failed PhII Hunt­ing­ton’s drug in lat­est pipeline prun­ing

Pfiz­er used one of its foot­notes in the Q1 re­port to sweep out an ex­per­i­men­tal Hunt­ing­ton’s drug that failed re­cent­ly in a Phase II tri­al, the lat­est in a long se­ries of im­plo­sions in the neu­ro­science field.

Pfiz­er didn’t ex­plain what went wrong for PF-02545920, but in a blog post at HD­Buzz in De­cem­ber, which was edit­ed by one of the in­ves­ti­ga­tors in the study, the drug was writ­ten off as a com­plete flop in im­prov­ing the abil­i­ty of pa­tients to func­tion bet­ter — or boost scores on any oth­er symp­toms eval­u­at­ed in the 271-pa­tient tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.